SCHEMBL20213481

SCHEMBL20213481

O=C(c1nc2n(n1)CCOC2c1ccccc1)N1CC(F)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20221908 0.86 RIPK1 (1.00) RIPK1
SCHEMBL30014738 0.86 RIPK1 (1.00) RIPK1
SCHEMBL20213531 0.86 RIPK1 (1.00) RIPK1
SCHEMBL30014925 0.83 RIPK1 (0.76) RIPK1
SCHEMBL18366869 0.83 RIPK1 (0.76) RIPK1
SCHEMBL22736876 0.81 RIPK1 (0.72) RIPK1
SCHEMBL19658966 0.81 RIPK1 (0.76) RIPK1
SCHEMBL20221907 0.81 RIPK1 (1.00) RIPK1
SCHEMBL18366874 0.78 RIPK1 (0.71) RIPK1
SCHEMBL24310574 0.77 RIPK1 (0.70) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3548484-B1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2025-04-30 EP claimed
CN-110023313-B Bicyclic amide compounds and methods of use thereof 豪夫迈·罗氏有限公司 2022-10-25 CN claimed
EP-3548484-B1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2025-04-30 EP disclosed
US-11607396-B2 Bicyclic amide compounds and methods of use thereof GENENTECH, INC. (US) 2023-03-21 US disclosed
US-11071721-B2 Bicyclic amide compounds and methods of use thereof GENENTECH, INC. (US) 2021-07-27 US disclosed
US-11071721-B2 Bicyclic amide compounds and methods of use thereof GENENTECH, INC. (US) 2021-07-27 US disclosed
US-10933036-B2 2021-03-02 US disclosed
US-10933036-B2 2021-03-02 US disclosed
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-07 US disclosed
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-07 US disclosed
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11607396-B2 Bicyclic amide compounds and methods of use thereof CYP4B1, CYP1B1, AADAC RIPK1 4061/4885
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF CYP4B1, CYP1B1, AADAC RIPK1 4061/4885
US-11071721-B2 Bicyclic amide compounds and methods of use thereof CYP4B1, CYP1B1, AADAC RIPK1 4061/4885
US-10933036-B2 CYP1B1, CYP4B1, CYP11B2 RIPK1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.